Nasal and pulmonary vaccine delivery using particulate carriers

From National Research Council Canada

DOIResolve DOI: https://doi.org/10.1517/17425247.2015.1044435
AuthorSearch for: 1 ; Search for: 1 ; Search for:
Name affiliation
  1. National Research Council Canada. Human Health Therapeutics
FormatText
TypeArticle
Journal titleExpert Opinion on Drug Delivery
ISSN1742-5247
Volume12
Issue6
Pages9931008; # of pages: 16
SubjectBCG vaccine; chemokine receptor CCR7; chickenpox measles mumps rubella vaccine; chitosan nanoparticle; cholera toxin; diphtheria pertussis poliomyelitis tetanus Haemophilus influenzae type b vaccine; diphtheria pertussis tetanus vaccine; diphtheria vaccine; DNA vaccine; gamma interferon; gold nanoparticle; Haemophilus influenzae type b vaccine; influenza vaccine; interleukin 12; interleukin 18; interleukin 2; ISCOM; liposome; macrogol; measles mumps rubella vaccine; measles vaccine; Pneumococcus vaccine; polyethyleneimine; polylactic acid; polymer; severe acute respiratory syndrome vaccine; tumor necrosis factor alpha; vaccine; virosome; adaptive immunity; antigen presenting cell; B lymphocyte; CD4+ T lymphocyte; CD8+ T lymphocyte; cross presentation; Haemophilus infection; human; influenza; influenza A (H5N1); inhalation; innate immunity; measles; mucosal immunity; nanoemulsion; pertussis; pneumococcal infection; respiratory tract infection; severe acute respiratory syndrome; T lymphocyte; tuberculosis; virus like agent
Abstract
Publication date
PublisherTaylor & Francis Group
Terms of use
LanguageEnglish
Peer reviewedYes
NPARC number21275842
Export citationExport as RIS
Report a correctionReport a correction
Record identifier1384740e-029f-41ad-9fe8-a6bc97ec2247
Record created2015-07-14
Record modified2016-05-09
Date modified: